CREATE-X a role for capecitabine in early-stage breast cancer: an analysis of available data.

NPJ Breast Cancer · 2017 · PMC5519731 · PMID 28758147

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a positive trendno p-value reported

A positive trend was seen in DFS (HR 0.84) combined with the statistically significant, and greater, OS advantage (HR 0.68) seen in the secondary analysis (this time driven analysis was scheduled to occur in 2012 and the patent expiration in the U.S. for capecitabine was December 14, 2013).

also in 11,005 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.